CLOV rides 38% Medicare Advantage growth and rising EBITDA, but higher medical costs and policy risks cloud its near-term margin outlook.
Clover Health Investments is now a contrarian buy, with the market underestimating its path to profitability in 2026. CLOV's member retention exceeds 90%, older cohorts generate $217 monthly profit, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results